Healthcare
Live Price
Offline$8.99
+0.45% today
1Y Change
-8.11%
Window
Jun 25, 2025 โ Jun 17, 2026
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
BioCryst Pharmaceuticals, Inc. (BCRX) is a Healthcare stock with a market cap of $1.90B. The stock last traded around $8.99 and down 8.1% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +94.1%, EPS growth of +393.0%, a dividend yield of 0.0%. What stands out right now is revenue +94.1%, EPS +393.0%, free cash flow +716.1% with operating margin 39.0% and ROIC 93.9%. Valuation is more restrained than many high-expectation growth names at P/E 7.2 and price/sales 2.2. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines BCRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+94.1% vs +7.6% peer median
Operating Margin
Above sector median
+39.0% vs +19.4% peer median
P/E
Below sector median
7.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 4, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +94.1% and EPS at +393.0%, with operating margin around 39.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.9% over the next 5 trading days and finished higher after 2 of those reports.
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 4, 2026 | โ | -1.8% | -6.7% | -9.3% |
2026 Feb 26, 2026 | +1500.0% | +10.8% | +7.6% | +21.0% |
2025 Nov 3, 2025 | -14.3% | -1.5% | +5.0% | +4.4% |
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
BCRX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
BCRX Max Drawdown
-35.93%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for BCRX and SPY.
Company Overview
BioCryst Pharmaceuticals, Inc.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.